

PHARMING

PHARMING REDEEMS SIXTH TRANCHE OF CONVERTIBLE BOND

Leiden, The Netherlands, July 29, 2013. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announced that it has redeemed the sixth tranche of its €16.35 million convertible bond. A total of 18,799,840 shares were issued to the bondholders under the terms and conditions of the bond, serving as a pre-installment for the August 28, 2013 redemption and interest payment.

As of today, the number of outstanding shares has increased to 229,042,869.

About the January 2013 Convertible Bonds

As announced in our press release on 16 January 2013, and following the approval of the increase of the Company’s authorized share capital during the extraordinary general meeting of shareholders, which was held on February 28, 2013, Pharming redeems the bond on a month by month basis in seven equal tranches, such that the bond will be redeemed in full on 1 October 2013. Pharming can decide at its discretion to redeem the bond and pay the interest due, by means of monthly equity tranches or cash payments, of which six of the seven have now been redeemed, such that redemption of the bond will be completed on 1 October 2013. The remaining redemption date is 1 October.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum. RUCONEST® is partnered with Santarus, Inc. (NASDAQ: SNTS) in North America and a Biologics License Application (BLA) for RUCONEST® is under review by the U.S. Food and Drug Administration. The product is also being evaluated for various follow-on indications. Pharming has a unique GMP compliant, validated platform for the production of recombinant human proteins that has proven capable of producing industrial volumes of high quality recombinant human protein in a more economical way compared to current cell based technologies. In July 2013, the Platform was partnered with Shanghai Institute for Pharmaceutical Industry (SIPI), a Sinopharm Company, for joint global development of new products. Pre-clinical development and manufacturing will take place at SIPI and are funded by SIPI. Pharming and SIPI initially plan to utilise this platform for the development of rhFVIII for the treatment of Haemophilia A. Additional information is available on the Pharming website, www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact

Sijmen de Vries, CEO: T: +31 71 524 7400

FTI Consulting

Julia Phillips/ John Dineen, T: +44 (0)207 269 7193

###